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OBJECTIVE — The purpose of this study was to report the prevalence of the International
Diabetes Federation (IDF)–deﬁned metabolic syndrome and its components among a cross-
sectional sample of racially/ethnically diverse eighth grade youths and examine the association
between the presence of the syndrome and participant fasting insulin and homeostasis model
assessment of insulin resistance (HOMA-IR) levels.
RESEARCH DESIGN AND METHODS — Data were from a cross-sectional study with
1,453 racially/ethnically diverse eighth grade students from 12 middle schools in three U.S.
states (Texas, North Carolina, and California). Height, weight, waist circumference, and blood
pressurewererecorded.Fastingbloodsampleswereanalyzedfortriglycerides,HDLcholesterol,
glucose, and insulin; HOMA-IR was calculated. Sex, race/ethnicity, and pubertal stage were
self-reported.IDFcriteriawereusedtodeterminetheprevalenceofthemetabolicsyndrome.The
odds ratio for being classiﬁed with the syndrome was calculated by quintiles of fasting insulin
and HOMA-IR.
RESULTS — Of the sample, 138 students (9.5%) were classiﬁed with metabolic syndrome.
Hispanics were more likely to have high abdominal adiposity and high triglycerides. Male
adolescents were more likely to have high triglycerides, low HDL cholesterol, high blood pres-
sure, and high fasting glucose. Participants in the highest insulin quintile were almost 200 times
more likely to be classiﬁed with the syndrome than participants in the lowest quintile with
comparable associations for HOMA-IR quintiles.
CONCLUSIONS — In a racially/ethnically diverse sample of U.S. adolescents, 9.5% of par-
ticipants were identiﬁed with the metabolic syndrome using the IDF criteria. The likelihood of
metabolic syndrome classiﬁcation signiﬁcantly increased with higher insulin and HOMA-IR
values.
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T
hemetabolicsyndromeisassociated
with an increased risk of develop-
ment of type 2 diabetes and cardio-
vascular disease (CVD) (1–3). Although a
joint statement from the American Diabe-
tes Association and the European Associ-
ation for the Study of Diabetes raised
concerns about whether the presence of
the syndrome conveys a risk of heart dis-
ease beyond that of the individual com-
ponents (3), it is clear that adults with
metabolic syndrome are more likely to
develop CVD. Metabolic syndrome risk
factors (4,5) in childhood have also been
shown to predict the likelihood of pos-
sessing the metabolic syndrome and type
2 diabetes in adulthood (4). Determina-
tionofpediatricprevalencerateshasbeen
hampered by the lack of a consistent def-
inition for metabolic syndrome in chil-
dren, with investigators creating their
own deﬁnitions (6–9).
The International Diabetes Federa-
tion (IDF) proposed a deﬁnition that can
be applied globally. According to the IDF
criteria, an adolescent has metabolic syn-
drome if he or she has abdominal obesity
(waist circumference 90th percentile)
and two of the following: triglycerides 
1.7 mmol/l; HDL cholesterol 1.03
mmol/l; blood pressure  130 mmHg
systolic or 85 mmHg diastolic; or glu-
cose 5.6 mmol/l (10). A recent analysis
of the National Health and Nutrition Ex-
amination Survey (NHANES) reported
that 4.5% of U.S. 12- to 19-year-old ado-
lescents were classiﬁed with the syn-
drome (11) using the IDF criteria. There
is a need to apply these new criteria to
alternative datasets to compare metabolic
syndrome prevalence rates across studies
and facilitate monitoring of temporal
trends.
Although metabolic syndrome has
been referred to as the insulin resistance
syndrome (12), the IDF criteria do not
include either fasting insulin level or the
homeostasis model of insulin resistance
(HOMA-IR) (13). There has been debate
about the extent to which the metabolic
syndrome deﬁnes the risk of CVD associ-
ated with insulin resistance beyond the
risk associated with classic CVD risk fac-
tors (obesity, HDL, triglycerides, and
blood pressure) (3). Therefore, it would
be useful to understand the extent to
which the presence of the syndrome is
associatedwithinsulinresistance.Thisar-
ticle reports 1) the prevalence of the IDF-
deﬁned metabolic syndrome among a
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verse eighth grade youths, 2) the compo-
nents of the syndrome among those
participants, and 3) the association be-
tween the presence of the syndrome and
participant fasting insulin and HOMA-IR
levels.
RESEARCH DESIGN AND
METHODS— The data presented
here are from a pilot study conducted by
the Studies to Treat or Prevent Pediatric
Type 2 Diabetes (STOPP-T2D) Preven-
tion Study Group. STOPP-T2D Preven-
tionisaNationalInstituteofDiabetesand
Digestive and Kidney Diseases multisite
study designed to reduce the prevalence
of risk factors for type 2 diabetes among
middle school children. Data were col-
lected at three ﬁeld centers in Texas (Bay-
lor College of Medicine), California
(University of California, Irvine), and
North Carolina (University of North
CarolinaatChapelHill).TheSTOPP-T2D
coordinating center is at The George
Washington University Biostatistics Cen-
ter (Washington, D.C.). The four institu-
tional review boards approved this study.
Participant recruitment methods and
inclusioncriteriahavebeenreportedelse-
where (14). In brief, participants were
eighth grade students recruited from 12
schools (4 per ﬁeld center), in which at
least 50% of the participants were from a
race/ethnicitythathasanincreasedriskof
development of type 2 diabetes (black,
Native American, or Hispanic). Schools
were also required to have at least 50% of
their enrolled students eligible for free or
reduced price school lunch. All eighth
grade students who provided written pa-
rental consent and childhood assent and
who did not have a diagnosis of either
type 1 or type 2 diabetes were eligible to
participate. Participants received 50 USD
and a free breakfast for participating in
the study.
Participant race/ethnicity and sex
wereobtainedbyself-report.Pubertalde-
velopmentwasself-assessedusingthePu-
bertal Development Scale (15). Height
was measured to the nearest 0.1 cm on a
stadiometer (PE-AIM-101; Perspective
Enterprises,Kalamazoo,MI)withthepar-
ticipants shoeless and the head in the
Frankfort plane. Body weight was mea-
sured to the nearest 0.1 kg using a preca-
librated electronic scale (SECA Alpha
882; Vogel & Halke, Hamburg, Ger-
many) with the participants shoeless and
pockets empty. BMI (weight in kilograms
divided by the square of height in meters)
and BMI percentiles were then calculated
using Centers for Disease Control and
Prevention age- and sex-speciﬁc percen-
tiles, and participants were grouped as
normal weight (BMI 85th percentile),
overweight (85th percentile  BMI
95th percentile), and obese (BMI
95th percentile). Waist circumference
was assessed to the nearest 0.1 cm at the
lateral border of the right iliac crest ac-
cording to the NHANES protocol with
use of a weighted measuring tape by re-
search assistants who were within 90%
agreement with a criterion observer dur-
ing a prestudy training procedure. Blood
pressure was recorded three times using
an automated blood pressure monitor
(Omron HEM-907; Omron Healthcare,
Vernon Hills, IL). The initial measure-
ment was taken after the participant had
been seated quietly for 5 min, and each
subsequent value was recorded 1 min af-
ter the preceding measurement. The
mean of the second and third measure-
ments was used in all analyses.
Participants were called the night be-
fore the blood sampling and were re-
mindedthattheyneededtofastbeforethe
test. At the beginning of the blood sam-
pling, participants were asked when they
last ate, and any participant who reported
eating or drinking after midnight was
considered nonfasting and was asked to
return another day when he or she would
still receive the incentive. No participants
reported taking any lipid-lowering or an-
tihypertensive medications. Fasting ve-
nous blood samples were obtained by
experienced phlebotomists. Blood was
collected in 2-ml Vacutainers (Becton
Dickinson, Franklin Lakes, NJ). Vacu-
tainers containing sodium ﬂuoride and
sodium heparin were used to collect
bloodforglucoseandinsulinsamples,re-
spectively. Cholesterol samples were col-
lected in EDTA tubes. Blood was spun
andseparatedintoserumandplasma,fro-
zen, packed in dry ice, and shipped to the
Northwest Lipid Metabolism and Diabe-
tes Research Laboratory at the University
of Washington. Measurement of lipopro-
tein fractions (for HDL cholesterol) and
triglycerides were performed enzymati-
cally using a Hitachi 917 autoanalyzer
and Centers for Disease Control and Pre-
vention standardized procedures. The in-
terassaycoefﬁcientsofvariation(CVs)are
consistently 1.5% for total cholesterol
and triglycerides and 2% for HDL cho-
lesterol for this laboratory. Glucose was
assessed using the same analyzer and re-
agent from Roche Diagnostics. Insulin
was determined using a double-antibody
radioimmunoassay (16). The between-
assay CVs of the two low- and high-
insulin quality control samples were 6.9
and 4.6%, respectively. The CV on blind
split duplicates was consistently 8.0%.
HOMA-IR was computed according to
the formula: (glucose  insulin)/22.5
(13).
Statistical analysis
Descriptive statistics including means,
SDs, and percentages were calculated for
all variables. Generalized estimating
equation models that took into account
the clustering of observations within
schoolswereusedtotestfordifferencesin
thepercentageofstudentswithmetabolic
syndrome as deﬁned by each measure-
ment,themeannumberofmetabolicsyn-
drome abnormalities, and mean insulin
levels and HOMA-IR for those with and
without metabolic syndrome. Equal cor-
relation between all interschool observa-
tions (exchangeable) was chosen as the
covariance structure. Associations be-
tween sex and race/ethnicity and each of
the metabolic syndrome components
were determined using logistic regression
models. Logistic regression generalized
estimating equation models were used to
predictmetabolicsyndromebyquintileof
insulin and HOMA-IR before and after
adjustmentforsex,pubertalstage,andra-
cial/ethnic group. To explore whether re-
sults differed by racial/ethnic groups, the
models with the interaction between ra-
cial/ethnic group and our primary expo-
surevariables(insulinorHOMA-IR)were
rerun. Unfortunately, none of these mod-
elswouldconvergebecausetherewascol-
linearity between school and race, with
someschoolsalmostexclusivelycompris-
ing a single racial/ethnic group. As partic-
ipants were clustered within schools and
the data are from a cluster-designed trial,
it is not appropriate to rerun the analysis
independent of school, and therefore
these analyses could not be performed.
All descriptive data from this pilot study
of a multisite trial are considered explor-
atory and thus all P values are presented
without adjustment for multiple compar-
isons. SAS statistical software (version
9.1; SAS Institute, Cary NC) was used for
all statistical analyses.
RESULTS— A total of 1,740 eighth
grade students participated in the study.
After exclusion of 135 students with in-
complete data required for the various
metabolic syndrome deﬁnitions and 8
STOPP-T2D Prevention Study Group
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the blood sampling, a total of 1,597 stu-
dentsremained.Becausestandardizedcut
points for waist circumference are only
available for white, black, and Hispanic
children (17), an additional 144 students
with any other race/ethnicity were ex-
cluded, leaving 1,453 students for these
analyses.
Of the 1,453 eighth grade partici-
pantsincludedintheanalyses,828(57%)
were female, 844 (58%) were Hispanic,
367 (25%) were black, and 242 (17%)
were white. Fifty percent (733) were nor-
mal weight (BMI 85th percentile),
20.9% were overweight (85th  BMI 
95th percentile), and 28.6% were obese
(BMI95thpercentile).Only122(8.5%)
of the participants were Tanner stage I or
II,370(25.6%)wereTannerstageIII,853
(59.1%) were Tanner stage IV, and 98
(6.8%) were Tanner stage V with 10 stu-
dents having missing values for Tanner
stage. Mean values for each of the meta-
bolic syndrome components and BMI are
presented for all participants and sepa-
rately for participants with and without
the syndrome in Table 1. The P values in
Table 1 are for regression models testing
fordifferencesinthemeanvaluesforeach
risk factor between participants classiﬁed
with and without the syndrome. Mean
values for each risk factor were signiﬁ-
cantly higher among participants who
wereclassiﬁedwiththesyndrome(Table1).
Of the participants, 138 students met
the IDF criteria for metabolic syndrome.
The prevalence of each component of the
syndrome is shown for each sex stratiﬁed
by race/ethnicity in Table 2. There were
signiﬁcant (P  0.05) racial/ethnic differ-
ences in the presence of high waist cir-
cumferencewiththehighestlevelsamong
the Hispanic male adolescents (25 vs. 21
and 16%), and a similar pattern was also
evident for the female adolescents. Fewer
black male adolescents had high triglyc-
erides than white or Hispanic male ado-
lescents (3 vs. 9 and 10%). The same
patternwasalsoevidentforlowHDLcho-
lesterol, in cholesterol, which fewer black
male adolescents (21%) had low HDL
cholesterol than either Hispanic (41%) or
white (46%) male adolescents. Similarly,
fewerblackfemaleadolescents(11%)had
low HDL cholesterol than white (22%) or
Hispanic females adolescents (27%) (Ta-
ble 2).
Thus,138participantswereclassiﬁed
with metabolic syndrome. Of the 1,453





n Mean SD Min Max n Mean SD Min Max n Mean SD Min Max
Waist circumference (cm) 1,453 80.5 14.1 56 154 1,315 78.1 12.2 56 130 138 103.2 10.7 85 154 0.001
HDL (mg/dl) 1,453 47.3 11.9 19 94 1,315 48.5 11.7 22 94 138 35.0 5.1 19 55 0.001
Triglyceride (mg/dl) 1,453 77.6 43.6 13 375 1,315 71.6 35.4 13 312 138 134.6 67.0 36 375 0.001
Diastolic blood pressure (mmHg) 1,453 65.6 8.8 43 110 1,315 64.8 8.3 43 110 138 73.2 10.0 48 98 0.001
Systolic blood pressure (mmHg) 1,453 114.1 10.5 83 156 1,315 113.3 10.1 83 156 138 121.7 11.3 96 153 0.001
Fasting glucose (mg/dl) 1,453 97.9 7.2 75 123 1,315 97.4 7.1 75 123 138 103.1 6.2 84 123 0.001
BMI (kg/m
2) 1,453 24.2 5.8 14 56 1,315 23.4 5.1 14 50 138 32.5 5.1 24 56 0.001
Fasting insulin (U/ml) 1,444 30.2 19.2 3 209 1,308 27.6 16.3 3 209 136 55.3 25.6 16 160 0.001
HOMA-IR 1,444 7.4 4.9 1 48 1,308 6.7 4.1 1 48 136 14.2 6.9 4 46 0.001
*Logistic regression models testing for differences in mean values for participants classiﬁed with and without the IDF-deﬁned metabolic syndrome. Min, minimum;
Max, maximum.













No Yes No Yes No Yes No Yes No Yes
Male
Black 112 (79) 30 (21) 138 (97) 4 (3) 112 (79) 30 (21) 114 (80) 28 (20) 67 (47) 75 (53)
Hispanic 272 (75) 93 (25) 329 (90) 36 (10) 217 (59) 148 (41) 320 (88) 45 (12) 140 (38) 225 (62)
White 99 (84) 19 (16) 107 (91) 11 (9) 64 (54) 54 (46) 98 (83) 20 (17) 55 (47) 63 (53)
P  0.0337 P  0.0012 P  0.0001 P  0.066 P  0.0513
Female
Black 188 (84) 37 (16) 225 (100) 0 (0) 201 (89) 24 (11) 215 (96) 10 (4) 182 (81) 43 (19)
Hispanic 355 (74) 124 (26) 436 (91) 43 (9) 348 (73) 131 (27) 450 (94) 29 (6) 330 (69) 149 (31)
White 107 (86) 17 (14) 120 (97) 4 (3) 97 (78) 27 (22) 119 (96) 5 (4) 93 (75) 31 (25)
P  0.0065 P  * P  0.0001 P  0.1485 P  0.1055
Total 1,133 (78) 320 (22) 1,355 (93) 98 (7) 1,039 (72) 414 (28) 1,316 (91) 137 (9) 867 (60) 586 (40)
Dataaren(%).Pvaluesrepresenttestsforethnic/racialdifferenceswithinsexintheproportionofparticipantsclassiﬁedwithandwithouttheIDF-deﬁnedmetabolic
syndrome. *Model could not be assessed due to an empty cell.
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(22.0%)hadthemandatorywaistcircum-
ference greater than the 90th percentile.
Of the participants who had the syn-
drome, 125 (90.6%) had low HDL cho-
lesterol, 110 (79.7%) had high fasting
glucose, 44 (31.9%) had high blood pres-
sure, and 53 (38.4%) had high triglycer-
ides. Eight participants (5.8% of those
with syndrome) had all ﬁve risk factors,
40 (29.0%) had four risk factors, and 90
(65.2%)hadthreeriskfactors(datanotin
tabular form).
The mean fasting insulin and HOMA
values for 136 participants (2 students
with the syndrome were missing insulin
values) with metabolic syndrome were
51.2 U/ml and 12.9 HOMA units for
those with three components, 61.5
U/ml and 16.4 HOMA units for four
components, and 70.9 U/ml and 19.2
HOMA units for participants with all ﬁve
risk factors (data not in tabular form).
Logistic regression models predicting
thepresenceofthesyndromebyquintiles
of fasting insulin and HOMA-IR values
after adjustments for sex, racial/ethnic
group, and pubertal stage are shown in
Table 3. The odds of metabolic syndrome
increased rapidly with increasing insulin
levels; students in the third insulin quin-
tile group were 10 times more likely to
have the syndrome than those in the low-
est insulin quintile group and the odds
ratio (OR) increased to about 200 times
for those in the highest quintile group
compared with those in the lowest quin-
tile group (P  0.014 and P  0.001,
respectively). Comparable ORs (157.4,
26.2, 9.9, and 2.1 for the four quintile
groups) were obtained for unadjusted
models (data not in tabular form). Partic-
ipants in the highest HOMA-IR quintile
group were 200 times more likely to
have the syndrome than those in the low-
est quintile group (P  0.0001). In the
insulin model, female adolescents were
less likely to be categorized with the syn-
dromethanmaleadolescents(P0.009)
and in both the insulin and HOMA-IR
models,blackswerelesslikelytohavethe
syndrome than whites (both P  0.01).
The unadjusted ORs for the HOMA-IR
models were similar to those obtained for
theadjustedmodel(182.6,33.8,6.5,and
2.2 for each of the four quintile groups,
data not shown) (Table 3).
CONCLUSIONS— The data pre-
sented in this article show that 9.5% of a
racially and ethnically diverse sample of
U.S. eighth grade adolescents, 50% of
whom were overweight or obese, had the
metabolic syndrome on the basis of the
new IDF criteria for children. The preva-
lencerateinthissamplewasroughlydou-
ble the mean 4.5% prevalence rate that
wasreportedintheNHANES1999–2004
sample using the same criteria (11). A re-
cent NHANES article (11) also reported
that metabolic syndrome prevalence was
highest(7.1%)amongMexican-American
adolescents; the metabolic syndrome has
also been shown to be higher among
overweight adolescents (18). Thus, the
increased prevalence in our sample prob-
ably reﬂected the high percentage of par-
ticipants from racial/ethnic groups at
increased risk of type 2 diabetes and the
high prevalence of overweight/obesity
among our participants.
The IDF criteria are based on expert
opinion but have not been shown to pre-
dict future disease risk. Therefore, to fa-
cilitate comparison of our sample with
published data we also applied four pre-
viously reported adolescent metabolic
syndrome criteria to our data (6–9). The
criteria of Weiss et al. (9) yielded a prev-
alencerateof1.7%,thoseofCruzetal.(7)
yieldedarateof6.1%,thoseofCooketal.
(6) yielded a rate of 11.6%, and those of
de Ferannti et al. (8) yielded a rate of
14.3%. Thus, the IDF criteria produced a
prevalence estimate that is approximately
the mean of previously reported criteria,
thereby providing concurrent validity to
use of the IDF criteria as a reasonable
method of classifying adolescents with
metabolic syndrome.
More than 92% of students with the
syndrome had low HDL cholesterol,
whereas 80% had high fasting glucose
levels, indicating that these two compo-
nents were central to a participant being
classiﬁed with the syndrome. Waist cir-
cumference is essential to the IDF criteria
and has previously been shown to corre-
late strongly with HDL cholesterol (r 
0.47) and glucose (r  0.44) among
U.S. adolescents (19). Thus, the high per-
centage of participants with metabolic
syndrome on the basis of low HDL cho-
lesterol and high fasting glucose is also
probably a reﬂection of the emphasis that
the IDF criteria places on high waist
circumference.
More than 40% of all participants in
this study had high fasting glucose levels,
which is higher than the 10.8% that was
reported for 12- to 19-year-old adoles-
cents participating in the NHANES
1999–2002 survey (20). We have previ-
ously reported that the fasting glucose
levels of the participants in this study in-
creased with BMI group and that our fast-
ingglucoselevelsarecomparabletothose
of other studies that include subjects
across the weight spectrum (14,21). The
higher prevalence rate reported here
therefore probably reﬂects differences in
the criteria for high fasting glucose levels
as the IDF criteria use the 100 mg/dl
deﬁnitionrecommendedbytheAmerican
Diabetes Association (22), whereas the
analysis of the NHANES dataset used a
level of 110 mg/dl.
Similarly,only53(38.4%)ofourpar-
ticipants with the syndrome had high
triglycerides, but the triglyceride cut
point of 150 mg/dl is considerably higher
than the 110 mg/dl that has previously
been used for this age-group (6). Thus,
comparison of our ﬁndings with previous
data are difﬁcult because the risk catego-
ries for each of the metabolic syndrome
criteriahasnotbeenconsistent.Thesedif-
ferences underscore the need to adopt
Table 3—Logistic regression model predicting prevalence of metabolic syndrome by quintiles
of insulin and HOMA-IR values, adjusted for sex, pubertal stage, and racial/ethnic group
OR (95% CI) ZP
Insulin quintile group
Insulin: 39.1 U/ml 199.64 (31.29–1,273.70) 5.60 0.001
Insulin: 29.1–39.0 U/ml 30.23 (4.25–215.00) 3.41 0.0007
Insulin: 23.1–29.0 U/ml 10.29 (1.60–65.99) 2.46 0.0139
Insulin: 17.1–23.0 U/ml 2.20 (0.52–9.28) 1.08 0.2817
Insulin: 17.0 U/ml Referent — —
HOMA-IR quintile group
HOMA-IR: 10.0 HOMA units 210.88 (31.10–1,429.73) 5.47 0.0001
HOMA-IR: 7.0–10.0 HOMA units 36.70 (4.97–271.05) 3.61 0.0003
HOMA-IR: 5.5–7.0 HOMA units 6.62 (0.89–49.04) 1.92 0.0548
HOMA-IR: 4.0–5.5 HOMA units 2.26 (0.48–10.56) 1.12 0.2607
HOMA-IR: 4.0 HOMA units Referent — —
STOPP-T2D Prevention Study Group
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ria to facilitate comparison of data from
different studies.
Students in the highest quintile of in-
sulin values were about 200 times more
likely to be classiﬁed with metabolic syn-
drome than those in the lowest quintile
group with comparable ORs for HOMA-
IR quintiles. Similarly, the mean insulin
and HOMA-IR values increased with the
number of components. Thus, if future
epidemiological research shows that met-
abolic syndrome identiﬁes participants at
increased risk of CVD above the risk pro-
vided by classic CVD risk factors because
of insulin resistance, our ﬁndings suggest
that the IDF criteria are likely to capture
the increase in risk attributable to insulin
resistance.Themeaninsulinvalueforour
participants was 30.2 U/ml, which is
considerablyhigherthanthelevelthathas
previously been reported in other U.S.
samples (7,19), probably reﬂecting the
high rate of obesity and the racial/ethnic
diversityofourparticipants.Therelation-
ship between insulin and metabolic syn-
drome might be different in other
samples. Nevertheless, the key implica-
tion is that youths with high insulin and
HOMA-IR levels have a much greater
risk of being classiﬁed with metabolic
syndrome.
The speciﬁc metabolic syndrome
components differed by race/ethnicity
and sex. Hispanics were more likely to
have high fasting glucose than the other
racial/ethnic groups. The presence of low
HDL was substantially lower among the
black students than among the other two
racial/ethnic groups. Male adolescents
weremorelikelytohavelowHDLcholes-
terol, high blood pressure, and high fast-
ing glucose than female adolescents.
Collectively, these ﬁndings suggest that
understanding the presence of the indi-
vidual components of the syndrome by
participant characteristics is important as
preventioneffortsmaybemoresuccessful
if they are tailored to the risk factors that
are more likely to be present in each




(23), making comparison with other
studies difﬁcult. Insulin has also been
showntovarywithinindividuals(24)and
thus the categorization of participants’ in-
sulinlevelsbasedonasingleinsulinvalue
should be interpreted with caution.
HOMA-IR is a function of both insulin
and glucose, and glucose is included in
the syndrome criteria. Therefore, caution
is required when interpreting the associ-
ationswithHOMA-IR.Thedataarecross-
sectional, and it is not possible to identify
the direction of causality among meta-
bolic syndrome, insulin, and HOMA-IR.
Participants were predominately from
low-income households and from just
three U.S. states; therefore, it is not pos-
sible to generalize the ﬁndings to other
groups or to the wider population. Fi-
nally, the analyses identiﬁed the associa-
tions between the presence of the IDF-
deﬁned metabolic syndrome and fasting
insulin and HOMA-IR levels. The associ-
ation between fasting insulin levels and
the presence of the metabolic syndrome
highlightstheimportanceofinsulinresis-
tance in the development of the syn-
drome. However, insulin or HOMA-IR
cut points for the identiﬁcation of meta-
bolic syndrome were not identiﬁed, and
our data should not be used to formulate
clinical guidelines. Finally, the study is
limited by the collinerality between
school and racial/ethnic group in our
samples, which prevented us from fully
exploring racial/ethnic differences in as-
sociations, and therefore more work is
needed to revaluate our ﬁndings in other
datasets.
In summary, 9.5% of a racially/
ethnically diverse sample of U.S. adoles-
cents were identiﬁed with IDF-deﬁned
metabolic syndrome. The likelihood of
being classiﬁed with metabolic syndrome
increased with higher insulin and
HOMA-IR values, suggesting that the cri-
teria might provide a method of identify-
ing adolescents who could have an
increased risk of CVD and type 2 diabetes
because of insulin resistance.
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